Coronary artery disease is the most important cause of morbidity and mortality in patients with end-stage renal failure (RF). Hypercholesterolemia is an important risk factor for coronary heart disease. Patients with chronic renal failure (CRF) have difficulties in compliance with their care and treatment. Intermittent simvastatin treatment may help to increase compliance and can be a treatment alternative in patients with CRF at risk of coronary artery disease. We investigated the effects of simvastatin and compared intermittent with continuous simvastatin treatment in hypercholesterolamic patients with CRF.
END-STAGE RF patients are at high risk of atherosclerotic heart disease and dislipidemia is an important risk factor in these patients. 1) Therefore, the diagnosis and treatment of dyslipidemia is of vital importance. 2) Dietary modification is the first line treatment for hyperlipidemia in patients with normal kidney functions. 3) However, patients with end-stage RF require drug treatment for dyslipidemia. 4) Five large studies have shown that reduced LDL-C decreases the number of major coronary conditions both in patients with heart disease or at risk of heart disease. [5] [6] [7] [8] [9] There have been a number of studies showing that statins are effective and reliable [10] [11] [12] [13] [14] [15] although there has not been a prospective study with a long follow-up showing how statins decrease morbidity and mortality caused by hyperlipidemia in patients with end-stage RF accompanied by hypercholesterolemia.
Noncompliance is a common problem in the clinical treatment of patients with hyperlipidemia. 16) Patients on dialysis have to comply with a very difficult treatment regimen such as fluid restriction, diet, use of a lot of drugs every day, and dialysis three times a week, each of which lasts 3-4 hours. 17) They have difficulties in compliance with their treatment and care. 18) Intermittent statin use for the treatment of hyperlipidemia has been investigated and has been shown to be effective and reliable. [19] [20] [21] [22] [23] [24] However, there has not been a study investigating the effects of intermittent statins on hyperlipidemia in patients with end-stage RF. In fact, intermittent statin treatment may increase compliance and can be a treatment alternative in patients at high risk of coronary artery disease.
METHODS

Patient selection:
We investigated the lipid profiles of 422 patients on dialysis in our center. Lipid levels were measured two times at two week intervals. The median lipid levels were calculated and accordingly 40 patients with LDL-C levels of 130 mg/dL or more were enrolled in the study group. Exclusion criteria were as follows: use of lipid decreasing drugs, diabetes mellitus, hypothyroidism, active lung disease, persistent increase in liver enzymes with unknown reasons, unstable angina pectoris, a history of myocardial infarct or coronary bypass surgery in the last three months, use of corticosteroids or immunosuppressive drugs, chronic alcoholism, plasma triglyceride levels of 400 mg/dL or more, and being younger than 20 years old.
One hundred and twenty-six patients on dialysis in another dialysis unit of our center underwent lipid investigations and 19 patients with LDL-C levels of 130 mg/dL or more (12 females and 7 males) were assigned to a control group. Control patients did not use any lipid decreasing drugs and the mean age of the Vol 45 No 6 patients was 54 ± 13 years. They were instructed to follow a low cholesterol diet (a diet in which less than 30% of the total calories was provided by fatty food, the ratio of saturated fat is not more than 10%, and the amount of maximum cholesterol is 300 mg/day).
Patients underwent 4-hour hemodialysis at the rate of 300 mL/min three times a week. We used bicarbonate and the dialysis membranes cuprophan and hemofan (1.1-1.2 m 2 ). The Kt/V index for each session was at least 1.2. The causes of RF were hypertension (n = 5), chronic glomerulonephritis (n = 5), polycystic kidney disease (n = 4), chronic pyelonephritis (n = 3), kidney stones (n = 3), familial Mediterranean fever (n = 2), ureteral stones (n = 1), and vesicourethral reflux (n = 1). The cause was unknown in 11 patients. We obtained informed consent from the patients and approval from the hospital ethical committee. Study design: Patients were randomly assigned into two study groups of 20. One group received 10 mg simvastatin two hours after dinner every day for four months (continuous group). The other group received 20 mg simvastatin when they were on dialysis three times a week (intermittent group). During the treatment period, the doses and route of administration were not changed. Patients continued to receive the other drugs they had already been taking for other conditions. Follow-up: All patients underwent physical examination at the time of recruitment. Patients were visited by a physician and asked whether they took their drug regularly and whether they experienced any side effects. Tablets were counted to determine patient compliance at each visit. The following formula was used to determine the rate of patient compliance. Compliance = Number of Tablets Taken/Expected Treatment Period × 100
Complete blood count, blood sugar level, blood urea nitrogen, creatinin, sodium, potassium, calcium, phosphorus, total protein, albumin, alkaline phosphatase, aspartate transaminase (AST) alanine aminotransferase (ALT), gamma glutamyl transpeptidase (GGT), and creatine phosphokinase (CPK) were investigated in each patient at baseline and every month. Total cholesterol, LDL-C, HDL-C, and triglyceride levels were measured in the study groups at baseline and in the second, third, and fourth month of the study and in the control group at baseline and in the second and fourth month of the study. Analysis of specimens: All blood specimens were drawn into tubes without anticoagulant just before hemodialysis and after a fasting period of 10-12 hours. They were centrifuged for 30 minutes. Fresh blood specimens were used to analyze lipid and lipoprotein specimens.
Enzymatic measurements of TC, triglycerides, and HDL-C levels were performed using a Hitachi 912 autoanalyzer and Boehringer Mannheim kits. Enzymatic calorimetric measurements of TC, triglycerides, and HDL-C were conducted with CHOP-PAP, GPO-PAP, and the direct method respectively. LDL-C was calculated using the Friedewald formula (LDL-C = TC-[HDL-C + triglycerides / 5]). Statistical analysis: SPSS 8.0 software was used for the statistical computations. Continuous variables are expressed as the mean ± SD and were compared with the Mann-Whitney U test. Significance was set at a P value < 0.05. One way variance analysis was used to compare the lipid profiles of all the groups.
RESULTS
At the end of the study, there were 19 patients (8 females and 11 males; 51 ± 14 years) in the continuous group and 16 patients (9 females and 7 males; 46 ± 11 years) in the intermittent group (Table I) . Two patients started to receive peritoneal dialysis, one patient underwent kidney transplantation, one patient died, and one patient had a poor prognosis. As a result, five patients failed to complete the study.
There was no significant difference in the lipid values between the study and control groups. In fact, the LDL-C levels of the groups were 157, 152, and 157 mg/dL, respectively.
In the continuous group, plasma TC and LDL-C levels started to decrease significantly in the second month of the study. Total cholesterol levels were 234 mg/dL at baseline and decreased to 178 mg/dL. LDL-C levels decreased from 157 mg/dL to 93 mg/dL. TC/HDL-C and LDL-C/HDL-C, considered atherogenic indices, decreased in the second month of the study and continued to decrease till the end of the study (Table II) . At the end of the study, TC and LDL-C decreased by 23% and 39%, respectively (Table III) . LDL-C = low density lipoprotein cholesterol; HDL-C = high density lipoprotein cholesterol. Compared with the control group: *P < 0.001; **P = 0.001; ***P = 0.014; ****P = 0.018; *****P = 0.036. In the intermittent group, plasma TC and LDL-C levels started to decrease significantly in the second month of the study. Total cholesterol decreased from 232 mg/dL to 169 mg/dL and LDL-C decreased from 152 mg/dL to 90 mg/dL. Atherogenic indices significantly decreased (Table II) . Total cholesterol and LDL-C decreased by 26% and 40%, respectively (Table III) .
Plasma triglyceride values in the continuous group were significantly high at the end of the study at 4 months compared to baseline values. Triglyceride levels in the intermittent group increased significantly in the second month of the study, but there was not a significant increase and the levels even returned to baseline values at the end of 4 months (Table II) .
In the control group, plasma TC and LDL-C levels decreased significantly in the second and fourth months of the study; however, the resultant values were above normal. In addition, the atherogenic indices did not change. Triglyceride levels did not change significantly.
There were no significant differences in the lipid values in the continuous and intermittent groups between baseline values and the values obtained at the end of the study. In addition, there was no significant difference in the atherogenic indices between the two study groups (Table II) . Side-effects and patient compliance: There were no significant differences in the baseline biochemical parameters and those obtained at the end between the groups. However, patients in the control group suffered from more severe anemia. The mean hemoglobin values were 11.7 ± 2.2 g/dL, 13.9 ± 2.5 g/dL, and 9.1 ± 2.9 g/dL in the continuous, intermittent, and control groups (P = 0.02).
Patients did not suffer any side effects such as insomnia, myalgia, arthralgia, erythema, nausea, vomiting, headache, tremor, vertigo, memory loss, anxiety, depression, or an abnormal sense of taste, which are likely to be caused by statins.
The rate of compliance was 90% and 93.3% in the continuous and intermittent groups, respectively (P > 0.05).
Only one patient in the continuous group had a high level of CPK (male; 55 years old). In fact, CPK increased by two and a half times within the first month of the treatment; therefore, the treatment was withdrawn for one month. When CPK returned to baseline values, the treatment was started again. When CPK increased by seven and a half times after one-month of treatment, the treatment was discontinued. Despite the dramatic rise in CPK values, the patient was asymptomatic (Table IV) .
In the intermittent group, the increase in liver transaminase levels was high enough to warrant the withdrawal of treatment only in one patient (male; 57 years old). The patient suffered from chronic hepatitis C. There were no changes in liver function tests within two months of the treatment. However, within three months of the treatment, there was a six-fold increase in AST, 18-fold increase in Vol 45 No 6 ALT, and 15-fold increase in GGT. The values returned to normal after withdrawal of the treatment. There were no increases in ALP or bilirubin (Table IV ). In addition, there were no significant changes in biochemical parameters in either the continuous group or intermittent group other than the two patients mentioned above.
DISCUSSION
We found that intermittent simvastatin was as effective and reliable as continuous simvastatin in CRF patients. The effects of simvastatin taken every other day have been investigated before, but the studies were performed on patients with normal kidney function.
Studies performed thus far have showed an inverse relation between dosage and patient compliance. Claxton, et al found significantly higher rates of compliance with drugs taken once a day than those taken three times a day (P = 0.008) and four times a day (P < 0.001) and with drugs taken twice a day than those taken four times a day (P < 0.001). 25) Even a single dose did not ensure perfect compliance. However, it can be concluded that compliance increases as the dosage decreases.
To our knowledge, there has not been a study investigating the effects of simvastatin given only on dialysis in hypercholesterolemic CRF patients. As in all other chronic conditions, compliance is extremely important in CRF patients, who conventionally have had difficulties in compliance with their treatment. 18) Patients on dialysis have to comply with a very strict treatment regimen such as fluid restriction, diet, use of a lot of drugs every day, and 3 dialysis sessions a week, each of which lasts 3-4 hours. 17) Intermittent statins taken only on days when patients are on dialysis may both improve compliance and decrease side effects.
Statins have been shown to be effective on TC, LDL-C, and the atherogenic index in hypercholesterolemic patients on dialysis. Wanner, et al in their series of 40 patients on dialysis demonstrated that lovastatin and simvastatin considerably decreased TC and LDL-C, increased HDL-C, and had positive effects on the ratio of LDL-C to HDL-C. They revealed that simvastatin at 10 mg/day decreased serum TC by 23% and LDL-C by 31% (P < 0.01). 14) We found that intermittent treatment decreased TC and LDL-C by 26% and 40% respectively, and that continuous treatment decreased TC and LDL-C by 23% and 39%, respectively.
Patients are asked questions on whether they take their drug regularly, prescriptions are refilled, tablets are counted, and electronic monitoring is performed to determine the rate of compliance. Electronic monitoring is the gold standard for the determination of compliance. 26) In this study, we counted the number of tablets and found that the rate of compliance was 93.3% in the intermittent group and 90% in the continuous group (P > 0.05). These high rates of compliance can be explained by the fact that patients were informed about the benefits of the treatment and that their complaints were recorded and the tablets were counted at each visit. Actually, compliance can be improved when informed consent is obtained, patient complaints are taken into consideration, and patients are informed about the details of the treatment.
The efficacy and reliability of simvastatin given every other day have been investigated in patients with normal kidney function. One study revealed that simvastatin given every other day could be an alternative to daily simvastatin. 22) In another study, 40 mg fluvastatin every other day was shown to be as effective as 20 mg daily of fluvastatin in hypercholesterolemic patients. 20) Metz and Lucas reviewed articles and abstracts of articles written in English and published between 1996 and 2000 and attempted to determine the efficacy, reliability, and cost of simvastatin given every other day. They concluded that large randomized controlled studies are needed. 24) One study revealed that atorvastatin at a dose of 40 mg every other day decreased LDL-C by 39.9% and 40 mg week atorvastatin decreased LDL-C by 20.7% at the end of six-month treatment. 21) In another study, Matalka, et al reported that atorvastatin every other day and atorvastatin daily decreased LDL-C by 35% and 38%, respectively. 19) We found that 20 mg simvastatin given on the days of dialysis and 10 mg simvastatin daily decreased LDL-C by 40% and 39%, respectively. The rate of compliance was higher with intermittent simvastatin than continuous simvastatin, but the difference was not significant.
We used the Friedewald formula to determine LDL-C levels. One may think that the Friedewald formula is not reliable in patients with uremia as hypertrigly-ceridemia is frequently seen in these patients. It has been claimed that the formula is not acceptable in patients on dialysis. 27) Although one study revealed that the Friedewald formula is highly correlated with the reference method, 28) it seems logical that treatment should be based on LDL-C levels determined according to this formula as there is no better alternative.
A few studies have revealed that statins were reliable in RF patients. Wanner, et al detected a moderate increase in liver transaminases only in one patient and observed no side effects in other patients. 14) However, it has been reported that an RF patient on cyclosporine developed myoglobinuric renal failure after a four-year treatment with lovastatin (20 mg/day). 29) In the present study, liver transaminases increased in only one patient in the intermittent group, but they returned to normal after withdrawal of the treatment. CPK levels increased only in one patient in the continuous group, and they also returned to normal after withdrawal of the treatment.
In the present study, decreased TC and LDL-C values in the control group can be attributed to the diet. Therefore, the favorable effects of diet should always be kept in mind. 15) We did not investigate apolipoprotein levels. However, it has been shown that patients on dialysis may have abnormal apolipoprotein composition and lipoprotein particles although lipid levels are normal, which supports the idea that apolipoproteins are more sensitive indicators than lipids in uremic dislipidemia. 30) Both intermittent and continuous simvastatin treatment significantly decreased TC and LDL-C and did not cause any important side effects in hypercholesterolemic CRF patients. Conclusion: It is concluded that, when necessary, simvastatin given in dialysis can be an alternative treatment since both intermittent and continuous simvastatin treatments were not different with respect to their efficacy and reliability.
